GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(39678)

  • GC81319 structure
    GC813192,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose
    CAS: 150302-84-4
    Purity: >98.00%

    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose is an FGFR3 and BRAF binder, and is an isovaleryl sucrose ester that can be found in Atractylodes japonica.

  • GC81320 structure
    GC81320Papaveroline
    CAS: 574-77-6
    Purity: >98.00%

    Papaveroline is a Fyn tyrosine kinase inhibitor, Na +,K + -ATPase inhibitor with an IC 50 of 0.20 mM, Mg 2+ -ATPase inhibitor, K + -activated pNPPase inhibitor with an IC 50 of 1.51 mM, and apoptosis inducer [1] [2] [3] . Papaveroline binds to the active site of Fyn tyrosine kinase and forms stable interactions with pocket amino acid residues [1] . Papaveroline induces cell apoptosis, produces pycnotic and fragmented cell nuclei, and does not reduce intracellular ATP levels [3] . Papaveroline is a dopamine-derived neurotoxin candidate associated with the pathogenesis of Parkinson's disease [3] . Papaveroline can be used in the research of Alzheimer's disease and Parkinson's disease [3] .

  • GC81321 structure
    GC81321Pegpleranib sodium
    Purity: >98.00%

    Pegpleranib (Fovista) sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.

  • GC81322 structure
    GC81322PF-07245303
    CAS: 2655556-75-3
    Purity: >98.00%

    PF-07245303 is a ITK / TRK inhibitor.

  • GC81323 structure
    GC81323PDGFRA/CAIX/XII-IN-1
    Purity: >98.00%

    PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.

  • GC81324 structure
    GC81324FGF7p
    CAS: 2758194-43-1
    Purity: >99.00%

    FGF7p is a small molecule peptide and a potential bladder protector.

  • GC81325 structure
    GC81325VEGFR2-IN-84
    CAS: 861877-12-5
    Purity: >98.00%

    VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.

  • GC81326 structure
    GC81326Tyrosine ethyl ester
    CAS: 34081-17-9
    Purity: >98.00%

    Tyrosine ethyl ester exhibits antioxidant activity [1] .

  • GC81327 structure
    GC81327Papaveroline hydrochloride
    CAS: 28362-21-2
    Purity: >99.00%

    Papaveroline hydrochloride is an orally active Fyn tyrosine kinase inhibitor.

  • GC81328 structure
    GC81328GZD-552
    Purity: >98.00%

    GZD-552 is a potent orally active FAK inhibitor with a human FAK IC 50 of 5.8 nM.

  • GC81329 structure
    GC81329TCB-32 hydrochloride
    CAS: 169764-95-8
    Purity: >97.50%

    TCB-32 (Compound I-1) hydrochloride is a FGFR1 agonist with an EC 50 of 0.88 μM.

  • GC81330 structure
    GC81330MRL-SYKi
    CAS: 1312534-69-2
    Purity: >98.50%

    MRL-SYKi is a chemical probe for gain-of-function variants of spleen tyrosine kinase ( SYK ).

  • GC81331 structure
    GC81331Ladarutatug
    CAS: 3075939-11-3
    Purity: >95.00%

    Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO.

  • GC81332 structure
    GC81332Valancitug
    CAS: 2766342-47-4
    Purity: >97.50%

    Valancitug is a human monoclonal antibody targeting VEGFA.

  • GC81333 structure
    GC81333Low molecular weight protamine acetate
    Purity: >98.50%

    Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector.

  • GC81334 structure
    GC81334Peptide HRH acetate
    Purity: >97.00%

    Peptide HRH acetate is a polypeptide that specifically binds to VEGF receptors.

  • GC81335 structure
    GC81335MST3-IN-1 TFA
    Purity: >99.00%

    MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC 50 of 122.4 nM.

  • GC81336 structure
    GC81336KY19334
    CAS: 2319609-67-9
    Purity: >99.50%

    KY19334 is a CXXC5-DVL inhibitor.

  • GC81337 structure
    GC81337MR24 TFA
    Purity: >99.00%

    MR24 TFA, a G-5555 derivative, is a mammalian STE20-like ( MST ) kinase inhibitor.

  • GC81338 structure
    GC81338BCN512
    CAS: 346691-54-1
    Purity: >99.50%

    BCN512 is an inhibitor of SFRP1 that can inhibit tissue fibrosis.

  • GC81339 structure
    GC81339Taladegib hydrochloride
    CAS: 1258861-21-0
    Purity: >97.00%

    Taladegib (LY2940680) hydrochloride is a Smoothened ( SMO ) antagonist.

  • GC81340 structure
    GC81340WAY-362692
    CAS: 915763-27-8
    Purity: >99.50%

    WAY-362692 is a secreted frizzled-related protein ( sFRP-1 ) inhibitor ( IC 50 of 0.02 μM), targeting the netrin domain of sFRP-1.

  • GC81341 structure
    GC81341IKVAVC acetate
    Purity: >98.00%

    IKVAVC acetate is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus.

  • GC81342 structure
    GC81342CMF9
    Purity: >98.50%

    CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction.